DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company developing recombinant proteins to improve the lives of patients who experience a stroke or recurrent strokes and kidney diseases.
DiaMedica Therapeutics, Inc.
Two Carlson Parkway,
Suite 260
Minneapolis, MN 55447
DiaMedica Therapeutics Inc.
Scott Kellen
Chief Financial Officer
T: (763) 496-5192
F: (763) 710-4456
skellen@diamedica.com